The Effect of Perindopril on Cardiovascular Morbidity and Mortality in Patients With Diabetes in the EUROPA Study: Results From the PERSUADE Substudy

Daly, Caroline; Fox, Kim; Remme, W. J.; Bertrand, Michel E.; Ferrari, Roberto; Simoons, M. L.

doi:10.1016/j.accreview.2005.10.023

Cited by 21 publications

(27 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results, therefore, suggest that the concept of diabetes alone as an indication for treatment with ACE inhibitors or angiotensin receptor blockers was ostensibly not a widely accepted practice among the participating physicians (10,15).…”

Section: Discussionmentioning

confidence: 99%

Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada

Braga

Casanova

Teoh

et al. 2010

Canadian Journal of Cardiology

View full text Add to dashboard Cite

Baseline characteristics, therapeutic regimens and treatment successdefined as the achievement of a blood pressure (BP) of 130/80 mmHg or lower, glycosylated hemoglobin (A1C) of 7% or lower, low-density lipoprotein cholesterol (LDL-C) lower than 2.5 mmol/L and total cholesterol/ high-density lipoprotein cholesterol ratio lower than 4.0 -are reported. REsULTs: Overall, 46% of individuals had a BP that was above the Canadian Diabetes Association's recommended target. Of these, 11% were untreated, 28% were receiving monotherapy, 38% were not receiving an angiotensin-converting enzyme inhibitor and 16% were not receiving either an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker. Optimal A1C levels were achieved in 53% of patients. Of those who did not attain A1C targets, 3% were not on glucose-lowering pharmacotherapy and 27% were receiving monotherapy. A total of 74% of patients were treated with statins. Overall, 64% and 62%, respectively, met the target LDL-C and the target total cholesterol/high-density lipoprotein cholesterol ratio. Statins were not prescribed to 43% of patients with LDL-C above target. Antiplatelet therapy was implemented in 81% of patients. In total, 21% achieved the combined targets for BP, A1C and LDL-C. INTERPRETATION: A substantial proportion of patients did not achieve guideline-recommended targets and were not receiving evidence-based therapy for vascular protection two years after publication of the Canadian guidelines. More research is warranted, and novel and effective strategies must be tested and implemented to correct this ongoing treatment gap. RÉsULTATs : Dans l'ensemble, 46 % des participants avaient une TA supérieure à la cible recommandée par l'Association canadienne du diabète. De ce nombre, 11 % n'étaient pas traités, 28 % recevaient une monothérapie, 38 % ne recevaient pas d'inhibiteur des enzymes de conversion de l'angiotensine et 16 %, d'inhibiteur de l'enzyme de conversion de l'angiotensine ou d'antagoniste de réception de l'angiotensine. Cinquante-trois pour cent des patients ont atteint un taux d'A1c optimal. Chez ceux qui ne l'ont pas atteint, 3 % ne prenaient pas de pharmacothérapie pour abaisser leur glycémie et 27 % recevaient une monothérapie. Au total, 74 % étaient traités au moyen de statines. Dans l'ensemble, 64 % et 62 %, respectivement, respectaient le C-LDL ciblé et le ratio entre le cholestérol total et le cholestérol à lipoprotéines de haute densité. Quarante-trois pour cent des patients dont le C-LDL était supérieur à la cible n'avaient pas de prescription de statines. Chez 81 % des patients, un traitement antiplaquettaire était amorcé. Au total, 21 % ont atteint les cibles combinées de TA, d'A1c et de C-LDL. INTERPRÉTATION : Une forte proportion de patients n'atteignaient pas les cibles recommandées par les lignes directrices et ne recevaient pas de traitement probant pour assurer leur protection vasculaire deux ans après la publication des lignes directrices canadiennes. D'autres recherches s'imposent, et il faudra mettre à l...

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada

Braga

Casanova

Teoh

et al. 2010

Canadian Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…217 In the ONTARGET trial, telmisartan was equivalent to ramipril as regards a primary composite of death from cardiovascular causes, MI, stroke or hospitalization for heart failure, while combining the two drugs caused adverse events without further benefit. 134 Lipid-lowering drugs.…”

Section: Blockers Of the Renin-angiotensin-aldosterone Systemmentioning

confidence: 99%

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary

diabetes

Rydén

Grant

et al. 2014

Diabetes and Vascular Disease Research

179

View full text Add to dashboard Cite

“…Ta obserwacja była zgodna z danymi uzyskanymi w określonej wcześniej podgrupie chorych na cukrzycę [312]. Korzystny trend o podobnej wielkości stwierdzono w podgrupie chorych na cukrzycę w badaniu EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA), do którego włączono osoby z mniejszym ryzykiem sercowo--naczyniowym [313]. W badaniu ONTARGET porównano ramipril, lek z grupy ACE-I, i należący do ARB telmisartan w populacji obciążonej dużym ryzykiem, podobnej do oce-…”

Section: Inhibitory Układu Renina-angiotensyna--aldosteronunclassified

Wytyczne ESC dotyczące cukrzycy, stanu przedcukrzycowego i chorób układu sercowo- -naczyniowego opracowane we współpracy z EASD

Rydén

Grant

Anker³

et al. 2013

Kardiol Pol

View full text Add to dashboard Cite

The Effect of Perindopril on Cardiovascular Morbidity and Mortality in Patients With Diabetes in the EUROPA Study: Results From the PERSUADE Substudy

Cited by 21 publications

References 26 publications

Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada

Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary

Wytyczne ESC dotyczące cukrzycy, stanu przedcukrzycowego i chorób układu sercowo- -naczyniowego opracowane we współpracy z EASD

Contact Info

Product

Resources

About